Bone Biologics (BBLG) Non-Current Debt (2014 - 2019)

Bone Biologics (BBLG) has reported Non-Current Debt for 6 consecutive years, with $11.3 million the latest figure, recorded in Q4 2019.

• In Q4 2019, Non-Current Debt changed N/A year-over-year to $11.3 million; the TTM figure through Dec 2019 stood at $11.3 million (changed N/A YoY), while the FY2019 annual figure was $11.3 million, changed N/A from the prior year.
• Non-Current Debt rose to $11.3 million in Q4 2019 per BBLG's latest filing, from $9.0 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $11.3 million in Q4 2019 and bottomed at $3.8 million in Q1 2015.
• Historically, Non-Current Debt has averaged $6.9 million across 5 years, with a median of $6.7 million in 2017.
• Annual changes were most pronounced in 2015 — Non-Current Debt surged 1578.72% — and 2016, when it rose 7.16%.
• Bone Biologics' Non-Current Debt stood at $5.1 million in 2015, then jumped by 48.8% to $7.6 million in 2016, then gained by 8.81% to $8.2 million in 2017, then climbed by 9.36% to $9.0 million in 2018, then increased by 25.78% to $11.3 million in 2019.
• Business Quant data shows BBLG's Non-Current Debt at $11.3 million in Q4 2019, $9.0 million in Q3 2018, and $8.6 million in Q2 2018.